Wuwei Qingzhuo San Ameliorates Hyperlipidemia in Mice Fed With HFD by Regulating Metabolomics and Intestinal Flora Composition

Abstract

Hyperlipidemia is one of the most common metabolic disorders that threaten people’s health. Wuwei Qingzhuo San (WQS) is a traditional Mongolian medicine prescription, which is widely used in Mongolia for the treatment of hyperlipidemia. Our previous studies found that it has hypolipidemic and hepatoprotective effects on hyperlipidemic hamsters. However, the underlying lipid-lowering mechanisms of WQS and its relationship with intestinal flora are not yet clear. In this study, 16 S rRNA gene sequencing and metabolomics were performed to investigate the action mechanism of WQS on hyperlipidemic mice induced by a high-fat diet (HFD). As a result, metabolic pathway enrichment analysis revealed that the intervention of WQS had obviously modulated the metabolism of α-linolenic acid and linoleic acid and the biosynthesis of bile acids. 16 S rRNA sequencing showed that WQS had altered the composition of the intestinal microbiota in hyperlipidemic mice fed with HFD and, especially, adjusted the relative abundance ratio of Firmicutes/Bacteroides. These findings provide new evidence that WQS can improve HFD-induced hyperlipidemia by regulating metabolic disorders and intestinal flora imbalance.

Microbiome-Metabolome Analysis Insight into the Effects of the Extract of Phyllanthus emblica L. on High-Fat Diet-Induced Hyperlipidemia

“…This would help analyze the pathogenesis of hyperlipidemia and the mechanism of action of drugs. For example, a metabolomics study found that 12 biomarkers of metabolic disorders showed a trend of regression after treatment with Wuwei Qingzhuo San, suggesting that hyperlipidemia can be improved by improving metabolic disorders [54]. Our study identified eight key metabolites that could serve as potential markers closely associated with hyperlipidemia, including 3-Hydroxypicolinic acid, 4,5-Di-O-caffeoylquinic acid, berberine, betaine, L-Pipecolic acid, Monoethylhexyl phthalic acid, L-Palmitoylcarnitine, and Stearoylethanolamide.…”

Metabolomics analysis delineates the therapeutic effects of Yinlan Tiaozhi capsule on triton WR-1339 -induced hyperlipidemia in mice

“…Hyperlipidemia is characterized by abnormal lipid levels in the blood and constitutes a potentially harmful disease leading to CVDs with high mortality ( Ge et al, 2022 ). Previous studies found that YL may treat hyperlipidemia by modulating angiogenesis and suppressing inflammatory responses ( Chen et al, 2019 ; Xiao et al, 2023a ).…”

“…Hyperlipidemia is characterized by abnormal lipid levels in the blood and constitutes a potentially harmful disease leading to CVDs with high mortality (Ge et al, 2022). Previous studies found that YL…”

Metabolomic and lipidomic studies on the intervention of taurochenodeoxycholic acid in mice with hyperlipidemia

“…The control group was fed ordinary feed (containing 18.5% protein, 4.6% fat, 58.9% carbohydrate, 3.2% crude fiber, 6.8% ash, 1.28% calcium, and 0.92 phosphorus), and the other groups were fed HFD for 30 days (containing 22.5% crude protein, 24.2% crude fat, 3.2% crude fiber, 5.6% crude ash, 1.2% calcium, and 0.8% total phosphorus). At week 4, mouse serum was collected to detect the levels of four indicators: TG, TC, LDL-C, and HDL-C ( Li et al, 2022a ; Ge et al, 2022 ). The treatment group was continuously administered TCDCA (25, 50, and 100 mg/kg/day) ( Xu et al, 2023b ) and fenofibrate (50 mg/kg/day) ( Sohn et al, 2017 ) by gavage for 4 weeks.…”